Idera Pharmaceuticals Inc  

(Public, NASDAQ:IDRA)   Watch this stock  
Find more results for IDRA
+0.05 (2.59%)
Real-time:   10:56AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.91 - 1.99
52 week 1.32 - 2.87
Open 1.94
Vol / Avg. 311,212.00/2.27M
Mkt cap 385.84M
P/E     -
Div/yield     -
EPS -0.34
Shares 194.87M
Beta 2.20
Inst. own 37%
Feb 21, 2018
Idera Pharmaceuticals Inc at RBC Capital Markets Healthcare Conference - 3:05PM EST - Add to calendar
Jan 22, 2018
BioCryst Pharmaceuticals Inc and Idera Pharmaceuticals Inc to Announce Merger - M&A Call
Jan 10, 2018
Idera Pharmaceuticals Inc at JPMorgan Healthcare Conference - Webcast
Nov 29, 2017
Idera Pharmaceuticals Inc at Piper Jaffray Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -8859.76% -236.98%
Operating margin -8943.29% -239.26%
EBITD margin - -235.21%
Return on average assets -75.63% -37.36%
Return on average equity -85.11% -41.07%
Employees 62 -
CDP Score - -


167 Sidney St
CAMBRIDGE, MA 02139-4237
United States - Map
+1-617-6795500 (Phone)
+1-617-6795592 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company's drug candidates include IMO-8400, IMO-2125 and IMO-9200. The Company has designed TLR antagonists and agonists to act by modulating the activity of targeted TLRs. It is developing its 3GA technology to turn off the mRNA associated with disease causing genes.

Officers and directors

James A. Geraghty Independent Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Vincent J. Milano President, Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Louis J. Arcudi III Chief Financial Officer, Senior Vice President - Operations, Treasurer, Secretary
Age: 54
Bio & Compensation  - Reuters
Robert Clayton Fletcher Senior Vice President - Business Development and Strategic Planning
Age: 53
Bio & Compensation  - Reuters
Joanna C. Horobin M.D. Senior Vice President, Chief Medical Officer
Age: 61
Bio & Compensation  - Reuters
Robert A. Doody Jr. Vice President - Investor Relations and Corporate Communications
Bio & Compensation  - Reuters
William S. Reardon CPA Lead Independent Director
Age: 71
Bio & Compensation  - Reuters
Maxine Gowen Ph.D. Director
Age: 59
Bio & Compensation  - Reuters
Julian C. Baker Independent Director
Age: 50
Bio & Compensation  - Reuters
Mark Alan Goldberg M.D. Independent Director
Age: 62
Bio & Compensation  - Reuters